Cell Banking Outsourcing Market

SKU: DMHCIT5614 | Last Updated On: Sep 20 2022 | Available Formats

>Cell Banking Outsourcing Market Expected to reach a high CAGR of 15.2% By 2029:

Cell Banking Outsourcing Market is Segmented By Bank Type (Master Cell Banking, Working Cell Banking, Viral Cell Banking), By Cell Type (Stem Cell Banking, Cord Stem Cell Banking, Embryonic Stem Cell Banking, Adult Stem Cell Banking, Dental Stem Cell Banking, Induced Pluripotent Stem Cell Banking, Non-stem Cell Banking), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029

Cell Banking Outsourcing Market size was worth US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 15.2 % during the forecast period (2022-2029). A cell bank is a place where cells originating from various body fluids and organ tissue are stored for future use. Cells, cell lines, and tissues are collected, stored, characterized, and tested in the cell banking outsourcing sector.

Cell Banking Outsourcing Market Dynamics  

Cell Banking Outsourcing Market growth is driven by the increase in biopharmaceutical production, rise in research on cell and gene therapies, rise in chronic disease, intense need to develop novel therapies, rise in awareness of cell banking, among others. Rise in applications of stem cell is expected to drive the growth in the forecast period

Stem cell technology is a speedily developing technology that plays a major role in regenerative medicine, as it also serves the disciplines of tissue engineering, cellular therapeutics, developmental cell biology, gene therapy, chemical biology, and nanotechnology. Additionally, in September 2021, LifeCell International, a stem cell bank and provider of reproductive genetic testing services, revealed that it had raised Rs 225 crore from OrbiMed Asia Partners IV, one of the leading healthcare investment group. The existing LifeCell founders will also participate in this round by investing Rs 30 crore. Such fund raisings will lead to adoption of cell banking outsourcing services, driving the market growth.

In addition, in August 2021, REPROCELL have signed a strategic collaboration agreement with TEXCELL JAPAN, a TEXCELL Group Company for GMP iPSC (Good Manufacturing Practices - induced pluripotent stem cells) - Master Cell Banks (MCB) Manufacturing. With this agreement REPROCELL can outsource a portion of the MCB manufacturing process to TEXCELL's GMP facility, which has been approved by the European Medicines Agency (EMA), allowing for the establishment of GMP iPSC MCB. Such partnerships will therefore lead to drive the growth of this market due to adoption of services.

Furthermore, according to the news published in April 2022, titled 'Utilizing stem cells to support and aid cancer therapy', stem cells have demonstrated their ability to improve cancer treatment by repairing cells after heavy therapy, creating immune cells, and acting as therapeutic carriers. Such rise in applications of stem cell will boost the growth of cell banking outsourcing services, driving the market growth.

High cost of cell therapies, legal and challenging issues during cell collection is likely to hamper the market growth

The cost of stem cell therapy varies depending on the number of injections and the complexity of the treatment. Stem cell therapy can cost anywhere from $1,000 to $6,000 for a single injection. Some patients may require multiple injections which may increase the cost of the treatment to $25,000 or more.

COVID-19 Impact Analysis

Covid-19 has significantly impacted the cell banking outsourcing market due to the pause of different stem cell transplant practices across the world. For instance, according to the study published in Bone Marrow Transplantation, titled 'Impact of COVID-19 pandemic on the use and release of cord blood units facilitated by the French Cord Blood Banks Network: on behalf of the Agency of Biomedicine, Eurocord and the French Society of Bone Marrow Transplant and Cell Therapy (SFGM-TC)' in October 2021, to curb COVID-19 spread, national lockdowns, international border closures, airplane and rail circulation restrictions were implemented both internationally and within France, making stem cell procurement from foreign and national donors more difficult. In addition, transplant teams had to deal with unexpected events involving virus exposure in donors and harvest workers, which were likely to affect stem cell clearance for donation.

Cell Banking Outsourcing Market Segment Analysis

The induced pluripotent stem cell banking segment is expected to hold the largest share in this market segment

The pluripotent stem cell banking segment is expected to have a major share is the cell banking outsourcing services market and is expected to do the same over the forecast period. Human pluripotent stem cells, such as induced pluripotent stem cells (iPSCs), provide unprecedented opportunities for cell therapies to treat intractable diseases and injuries. iPSC is created from skin or blood cells that have been reprogrammed into an embryonic-like pluripotent state, allowing for the generation of an infinite supply of any type of human cell required for therapeutic applications. According to the study published in Current Protocols, titled 'Autologous Induced Pluripotent Stem Cell-Based Cell Therapies: Promise, Progress, and Challenges' in March 2021, human induced pluripotent stem cells (iPSCs) have promised, they can be used as a starting material for autologous or patient-specific stem cell-based therapy. The positive results confirm the claimed benefit of an autologous approach, a cell therapy product that can engraft without risk of immunological rejection, obviating the requirement for medication and its side effects. Such promising results of iPSCs will therefore lead to drive the market growth due to the adoption of cell banking outsourcing services for iPSCs, driving the segment growth.

In addition, in September 2021, I Peace, Inc., a Palo Alto-based biotech company specialising on induced pluripotent stem cell (iPSC) technology, has expanded its personalised iPSC banking service. In Japan, I Peace debuted its clinical-grade individualised iPSC banking service in 2020 and has already banked the iPSCs of numerous people. Such expansion of iPSC banking services will lead to rise in adoption of iPSC banking, driving this segment growth.

Moreover, rise in research funding for iPSC research in the United States is also expected to propel the market growth. For instance, according to the report published by the National Institute of Health in June 2021, the estimated funding for induced pluripotent stem cells in the United States for the year 2019 and 2020 was USD 607 million and USD 657 million respectively. Such a huge investment on iPSC will lead to rise in adoption of pluripotent stem cell services, driving the market growth.

Cell Banking Outsourcing Market Scope

Metrics

Details

Market CAGR

15.2%

Segments Covered

By Bank Type, By Cell Type, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

Cell Banking Outsourcing Market Geographical Analysis

North America region holds the largest market share of global cell banking outsourcing market

North America holds a significant share and is expected to do the same over the forecast period. The major factors driving the market growth in this region include the developed healthcare system, strong foothold of major biopharmaceutical companies, rise in chronic diseases, and rise in research funding in this region, among others.

The United States has a better healthcare infrastructure, as compared to most other developed countries. According to the April 2022 update from the National Cancer Institute (NCI), the national spending on cancer care is estimated at USD 208.9 billion in 2020. In addition, the increasing number of cancer cases is creating tremendous opportunities for the market players. The major market players are focusing on R&D activities, in order to launch new and reliable treatments in the market. Such factors are expected to drive the market growth in this region. In addition, according to the news published in February 2022, the United States has seen record number of organ transplants in 2021. The preliminary data from the United Network for Organ sharing says, the United States executed a record-breaking number of organ transplants in 2021, with more than 40,000 transplants performed annually for the first time in the country's history. Such rise in organ transplantations will lead to rise in adoption of cell banking services in the country, driving the market growth.

In addition, rise in the approvals for the cell therapies is also expected to boost the market growth in this region over the forecast period. For instance, in October 2021, United States Food and Drug Administration has approved Gilead’s Tecartus as the first and only Car T therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukemia. Therefore, the rising approvals for cell therapies will lead to drive the market growth due to the rise in adoption of cell banking services to store cell lines, driving the market growth.

Cell Banking Outsourcing Market Competitive Landscape

Cell Banking Outsourcing Market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Charles River Laboratories, Inc, Merck KGaA, Cryo-Cell International Inc., Clean Biologics, Goodwin Biotechnology Inc., LifeCell International Pvt. Ltd, SGS Life Sciences, among others. The major players are also involved in strategic alliances like acquisitions and collaborations to secure a position in the global market. For instance, In May 2022, Anja Health raised USD 4.5 million in seed funding to make cord blood stem cell banking accessible for everyone, regardless of race, socioeconomic status, or income. The new funding will be used to strengthen the company's leadership team, promote strategic growth, and foster its community, among others.

Key Companies to Watch

Merck KGaA

Overview: The Merck Group, branded and commonly known as Merck, is a German multinational science and technology company headquartered in Darmstadt, with about 57,000 employees and present in 66 countries. The group includes around 250 companies; the main company is Merck KGaA in Germany.

Product Portfolio: It includes products like Cell & Virus Banking and Storage.

Frequently Asked Questions

What is the Projected CAGR value of the Cell Banking Outsourcing Market?

Cell Banking Outsourcing Market is expected to grow at a CAGR of 15.2% during the forecasting period 2022-2029.

Which region controlled the global market during 2022-2029?

North America region Controls the Cell Banking Outsourcing Market during 2022-2029

Which is the fastest growing region in the Cell Banking Outsourcing Market?

Among all regions, Asia Pacific is the fastest growing market share during the forecast period 

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report



Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest